TFF and SEC, which feature easy scalability and are able to comply with good manufacturing practices (GMP), were already studied in the context of an EV-based strategy that intends to utilize HEK293-derived engineered EVs carrying an immunostimulatory cytokine fusion protein, the heterodimeric IL-15/lactadherin, for a targeted cancer immunotherapy approach [207]. This evidence concerns the gene MFGE8 and cancer.